Primary Angioplasty for Acute Myocardial Infarction — Is It Worth the Wait?

Publisher Website
Google Scholar
Abstract
Nearly two decades after clinical trials established that fibrinolytic therapy for acute myocardial infarction preserves left ventricular function and reduces mortality, there is evidence that mechanical reperfusion therapy is superior in reducing the rates of death, reinfarction, intracranial bleeding, reocclusion of the infarct-related artery, and recurrent ischemia. Initially introduced as an alternative to fibrinolytic therapy (to circumvent contraindications to its use and the risk of intracranial bleeding), primary percutaneous coronary intervention is now increasingly recognized as the reperfusion therapy of choice. The ability to restore robust coronary flow promptly in more than 90 percent of patients and the nearly linear . . .